Basocellular Skin Cancer about Three Patients Treated with Vismodegib Review of your Action Mechanism

Abstract

Vismodegib (Erivedge®) is a hedgehog pathway inhibitor and is approved to treat locally advanced or metastatic basal cell carcinoma (BCC) not suitable for surgery or radiation therapy. Our main objectives were to study the intimate mechanism of action of this novel drug and to present three cases of our casuistry, the clinically evaluated objective response rate (ORR), as a contribution to the literature.